<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Indian J Pharmacol</journal-id>
      <journal-id journal-id-type="publisher-id">IJPharm</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0253-7613</issn>
      <issn pub-type="epub">1998-3751</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24987186</article-id>
      <article-id pub-id-type="pmc">4071716</article-id>
      <article-id pub-id-type="publisher-id">IJPharm-46-341</article-id>
      <article-id pub-id-type="doi">10.4103/0253-7613.132195</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Drug Watch</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Levetiracetam-induced acute psychosis in a child</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Zaki</surname>
            <given-names>Syed Ahmed</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gupta</surname>
            <given-names>Saurabh</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Department of Pediatrics, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai, Maharashtra, India</aff>
      <author-notes>
        <corresp id="cor1"><bold>Correspondence to:</bold> Dr. Syed Ahmed Zaki, E-mail: <email xlink:href="drzakisyed@gmail.com">drzakisyed@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2014</year>
      </pub-date>
      <volume>46</volume>
      <issue>3</issue>
      <fpage>341</fpage>
      <lpage>342</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>5</month>
          <year>2013</year>
        </date>
        <date date-type="rev-recd">
          <day>28</day>
          <month>8</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>3</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Pharmacology</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Levetiracetam is well-tolerated and commonly used as a broad spectrum antiepileptic in both partial and generalized seizures. Few cases of levetiracetam-induced psychosis in children are reported in the literature. The present case of levetiracetam-induced acute psychosis highlights the adverse effect of this drug and also emphasizes the need for close monitoring of children on levetiracetam.</p>
      </abstract>
      <kwd-group>
        <title>KEY WORDS</title>
        <kwd>Antiepileptic drug</kwd>
        <kwd>children</kwd>
        <kwd>levetiracetam</kwd>
        <kwd>psychosis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-1">
      <title>Introduction</title>
      <p>Levetiracetam is an antiepileptic drug, which has a safe and proven efficacy in complex partial seizures, generalized tonic clonic seizures and myoclonic seizures. It is widely used as add-on therapy in patients with epileptic disorders.[<xref rid="ref1" ref-type="bibr">1</xref>] Though generally well-tolerated, it may cause some mild adverse reactions.[<xref rid="ref1" ref-type="bibr">1</xref>] However, psychosis associated with its use in children has rarely been reported.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>] We report a case of an 11-year-old girl who developed levetiracetam-induced psychosis.</p>
    </sec>
    <sec id="sec1-2">
      <title>Case Report</title>
      <p>An 11-year-old girl was brought to the outpatient department with the complaints of restlessness and &#x201C;talking to herself&#x201D; for 1 day. She described hallucinations of either seeing a ghost or of snakes crawling all over her body. She had a history of generalized tonic convulsions 8 days ago for which she was started on tablet levetiracetam by a private practitioner. The convulsion had lasted for 2 min and she recovered after the convulsion. She had been was advised half tablet (500 mg) levetiracetam twice a day (20 mg/kg/day). However, her mother misunderstood the dose and started with one tablet twice a day (40 mg/kg/day). There was no history of fever, vomiting, headache, abdominal pain, or urinary complaints. There was no history of other drug ingestion, contact with tuberculosis or head injury, or history of psychiatric illness in past or in other family members. There was no preceding stressful event at home or in school. Developmentally, the child was normal. She was studying in 5<sup>th</sup> grade had good academic performance. Birth and family history were insignificant.</p>
      <p>On examination, the child was afebrile and her vitals were normal. There was no icterus, pallor or rash. Central nervous system examination revealed a restless child with uninhibited behavior. She spoke excessively, but speech was not slurred. No other abnormalities were detected on systemic examination. Laboratory investigations, e.g., complete blood count, liver function, renal function tests, urine analysis and serum electrolytes, thyroid function tests and antinuclear antibody test were normal. Magnetic resonance imaging of brain and electroencephalography were also normal. Measurement of drug levels in blood facility is not available in our institution hence drug levels were not measured. Levetiracetam was stopped and oral olanzapine was started. The patient recovered from her psychotic symptoms within 72 h and was discharged. Olanzapine was stopped 10 days after the discharge. This type A class of adverse drug reaction was evaluated for causality and was found to have a probable/likely causal relationship with levetiracetam as per Naranjo algorithm.[<xref rid="ref4" ref-type="bibr">4</xref>]</p>
    </sec>
    <sec sec-type="discussion" id="sec1-3">
      <title>Discussion</title>
      <p>Levetiracetam, a piracetam analog, is a water-soluble pyrrolidone derivative ((S)-alpha-ethyl-2-oxo-pyrrolidine acetamide) with a novel chemical structure and unique mechanism of action. It exerts its antiepileptic effects by specifically binding to synaptic vesicle protein 2A (a 90-kDa-membrane protein), inhibiting calcium release from intra-neuronal stores, opposing the activity of negative modulators of gamma-amino butyric acid- and glycine-gated currents and inhibiting excessive synchronized activity between neurons.[<xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>] It also blocks zinc and beta-carbolines from interrupting chloride influx in the GABA and glycine receptors.[<xref rid="ref5" ref-type="bibr">5</xref>] And inhibits N-type calcium channels.[<xref rid="ref6" ref-type="bibr">6</xref>] It is absorbed through gastrointestinal tract with high oral bioavailability and is excreted unchanged through the kidneys. It is not associated with clinically significant pharmacokinetic interactions with other drugs, including other antiepileptic drugs.[<xref rid="ref6" ref-type="bibr">6</xref>]</p>
      <p>The usual effective dose is between 20 and 60 mg/kg/day. One can start at 20 mg/kg in two doses and increase every 1-2 weeks till 60 mg/kg/day. Though generally well-tolerated, it may cause some adverse reactions such as asthenia, ataxia, diplopia, dizziness, dysarthria, fatigue, headache, light-headedness, nystagmus, paresthesias, somnolence, and tremors. These are usually either dose related or transient. Behavioral effects including agitation, anxiety, depression, emotional lability, hallucinations, and psychosis also observed.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref6" ref-type="bibr">6</xref>] Psychiatric side-effects are seen in up to 13.3% in adults and 37.6% in pediatric patients. Of these, severe symptoms such as depression, agitation, or hostility, and psychotic behavior are observed in 0.7% of patients.[<xref rid="ref7" ref-type="bibr">7</xref>] Factors like young age, history of febrile convulsions, status epilepticus, previous history of seizure, poorly controlled seizures, previous psychiatric history or cognitive problems, sensory deprivation and rapid increase in the dose of levetiracetam can increase risk of adverse reactions.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref5" ref-type="bibr">5</xref><xref rid="ref8" ref-type="bibr">8</xref>] Lamotrigine co-therapy has been shown to have a protective effect against psychosis.[<xref rid="ref8" ref-type="bibr">8</xref>] Although, there is evidence that the drug may trigger behavioral disorders, there are reports that it may reduce hyperactivity, impulsivity, mood instability and aggression in autistic children.[<xref rid="ref9" ref-type="bibr">9</xref>] Levetiracetam-induced psychosis normally occurs about 1 week after the start of treatment. However, it has also been reported after long term treatment.[<xref rid="ref10" ref-type="bibr">10</xref>] <xref ref-type="table" rid="T1">Table 1</xref> documents some reported cases of levetiracetam-induced psychosis. Most of the patients had certain predisposing risk factors. In the present case, young age and high dose of levetiracetam at the onset were the two risk factors predisposing to psychosis.</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Reports of levetiracetam-induced psychosis and associated rise factors in literature</p>
        </caption>
        <graphic xlink:href="IJPharm-46-341-g001"/>
      </table-wrap>
      <p>Hence, the authors suggest that children prescribed this drug should be monitored particularly with regard to psychiatric adverse effects. Titration of medication over a period of days or weeks rather than administration of full dose since the beginning may be practiced minimizes these adverse effects.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgment</title>
      <p>We would like to thank the Dean for permitting us to publish this manuscript.</p>
    </ack>
    <fn-group>
      <fn fn-type="supported-by">
        <p><bold>Source of Support:</bold> Nil</p>
      </fn>
      <fn fn-type="conflict">
        <p><bold>Conflict Interest:</bold> No</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aggarwal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Probable psychosis associated with levetiracetam: A case report</article-title>
          <source>J Neuropsychiatry Clin Neurosci</source>
          <year>2011</year>
          <volume>23</volume>
          <fpage>E19</fpage>
          <lpage>20</lpage>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Youroukos</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lazopoulou</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Michelakou</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Karagianni</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Acute psychosis associated with levetiracetam</article-title>
          <source>Epileptic Disord</source>
          <year>2003</year>
          <volume>5</volume>
          <fpage>117</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">12875956</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kossoff</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Bergey</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Vining</surname>
              <given-names>EP</given-names>
            </name>
          </person-group>
          <article-title>Levetiracetam psychosis in children with epilepsy</article-title>
          <source>Epilepsia</source>
          <year>2001</year>
          <volume>42</volume>
          <fpage>1611</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">11879376</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zaki</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Adverse drug reaction and causality assessment scales</article-title>
          <source>Lung India</source>
          <year>2011</year>
          <volume>28</volume>
          <fpage>152</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">21712934</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dannaram</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Borra</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pulluri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jindal</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Levetiracetam-induced acute psychotic episode</article-title>
          <source>Innov Clin Neurosci</source>
          <year>2012</year>
          <volume>9</volume>
          <fpage>10</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="pmid">23198271</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shakya</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Dutta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gautam</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Hallucination in a seizure patient using levetiracetam: A case report</article-title>
          <source>Case Rep Med 2012</source>
          <year>2012</year>
          <comment>706243</comment>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Delanty</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tonner</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: Open-label, noncomparative, multicenter, long-term follow-up study</article-title>
          <source>Epilepsia</source>
          <year>2012</year>
          <volume>53</volume>
          <fpage>111</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">22050371</pub-id>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mula</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Trimble</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Yuen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Sander</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>Psychiatric adverse events during levetiracetam therapy</article-title>
          <source>Neurology</source>
          <year>2003</year>
          <volume>61</volume>
          <fpage>704</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">12963770</pub-id>
        </element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rugino</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Samsock</surname>
              <given-names>TC</given-names>
            </name>
          </person-group>
          <article-title>Levetiracetam in autistic children: An open-label study</article-title>
          <source>J Dev Behav Pediatr</source>
          <year>2002</year>
          <volume>23</volume>
          <fpage>225</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">12177568</pub-id>
        </element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bayerlein</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Frieling</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Beyer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kornhuber</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bleich</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced psychosis after long-term treatment with levetiracetam</article-title>
          <source>Can J Psychiatry</source>
          <year>2004</year>
          <volume>49</volume>
          <fpage>868</fpage>
          <pub-id pub-id-type="pmid">15679219</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
